Information  X 
Enter a valid email address

IQ-AI Limited (IQAI)

  Print      Mail a friend

Thursday 30 April, 2020

IQ-AI Limited

Delay in Publishing Final Year Accounts

RNS Number : 5225L
IQ-AI Limited
30 April 2020
 

IQ-AI Ltd

("IQ-AI" or the "Company")

 

31 December 2019 final year results announcement timing

 

IQ-AI announces that it will delay the announcement of its Final Year 2019 full year results, originally planned for the end of April, until early May. This will also ensure that the Company and its auditors have adequate time to complete their standard procedures given the current working restrictions. This delay is in line with the recent joint regulatory guidance from the FCA, the FRC and the PRA regarding reporting timeframes in the current environment.

 

The Directors of the Company accept responsibility for the contents of this announcement.

 

-ENDS-

 

For further information, please contact:

IQ-AI Limited

Trevor Brown/Vinod Kaushal/Qu Li

Tel: 020 7469 0930

Peterhouse Capital Limited (Financial Adviser and Broker)

Lucy Williams/Heena Karani

Tel: 020 7220 9797

 

 

About IQ-AI Ltd (iq-al.ltd) IQ-AI, Ltd, the parent company of Imaging Biometrics® and StoneChecker™, is focused on providing advanced and state-of-the-art medical software and related services. Imaging Biometrics develops and provides visualization and analytical solutions enabling clinicians to better diagnose and treat diseases with greater confidence. Through close collaboration with researchers and clinicians, sophisticated advancements are translated into platform-independent software plug-ins which can extend the base functionality of workstations, imaging systems, PACS, or medical viewers. By design, IB's advanced visualization software seamlessly integrates into routine workflows. Please visit  imagingbiometrics.com for more information. 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
STRKKKBPDBKDBQN

a d v e r t i s e m e n t